- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
More than 50,000 crystalenses implanted
Aliso Viejo, CA-Since FDA approval in 2003, more than 50,000 crystalens accommodating IOLs (eyeonics) have been implanted worldwide. Of these, 17,000 implants were with the crystalens SE second-generation lens (introduced in 2005), the company said in a prepared statement.
Aliso Viejo, CA-Since FDA approval in 2003, more than 50,000 crystalens accommodating IOLs (eyeonics) have been implanted worldwide. Of these, 17,000 implants were with the crystalens SE second-generation lens (introduced in 2005), the company said in a prepared statement.
"Demand for the crystalens by ophthalmologists and their patients has remained very strong, with implants up around 30% in the second quarter," said J. Andy Corley, eyeonics' chairman and chief executive officer. "This is due in part to our commitment that surgeons and patients alike see positive, hassle-free outcomes with crystalens implants.
"We are delighted that the adjustments to the design and the surgical protocol available with the crystalens SE have been received so positively, strengthening our market share in the premium lens channel," Corley added.
